Research programme: sodium channel blockers - Biogen

Drug Profile

Research programme: sodium channel blockers - Biogen

Alternative Names: CNV 1061436; CNV-3000164; CNV-3000223; Nav 1.7 blockers - Biogen

Latest Information Update: 24 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer Biogen
  • Class Analgesics; Small molecules
  • Mechanism of Action Nav1.7-voltage-gated-sodium-channel-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Epilepsy; Pain

Most Recent Events

  • 13 Jan 2014 Research programme: sodium channel blockers - Convergence Pharmaceuticals is available for licensing as of 13 Jan 2014.
  • 01 Apr 2013 Preclinical development is ongoing in United Kingdom
  • 01 Jan 2013 Preclinical trials in Epilepsy in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top